Dr Ivo Abraham Column: 1 Billion People Can Access Biosimilars; What About the Other 7 Billion?

November 30, 2022

Now that the world population has reached 8 billion, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, took a look at how high-income countries can increase accessibility to live-saving medicines to the 7 billion people who having limited access to biosimilars.

Biosimilar Business Recap: Progress for Insulin in Europe, Canada; Biocon Biologics' Viatris Acquisition Completed
Amneal, Kashiv Launch Filgrastim Biosimilar, Releuko
Regence: Biosimilar Adoption Leads to $37 Million Reduction in Annual Spending
What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars